Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.